Neurofilament-light and contactin-1 association with long-term brain atrophy in natalizumab-treated relapsing-remitting multiple sclerosis

Letter Medicine, General & Internal

Serum Neurofilament Light and Multiple Sclerosis Progression Independent of Acute Inflammation

Arie R. Gafson et al.

Summary: This cohort study examines the serum neurofilament light concentration as a biomarker in relation to disability progression in multiple sclerosis, without considering the presence of acute inflammation.

JAMA NETWORK OPEN (2022)

Add to Collection

Article Clinical Neurology

Serum NfL levels in the first five years predict 10-year thalamic fraction in patients with MS

Hrishikesh Lokhande et al.

Summary: This study investigated the association between early serum neurofilament light (sNfL) levels and 10-year regional brain volumes in multiple sclerosis (MS) patients. The findings suggest that early sNfL levels are correlated with thalamic volume after 10 years, indicating the potential value of sNfL as a prognostic biomarker in MS.

MULTIPLE SCLEROSIS JOURNAL-EXPERIMENTAL TRANSLATIONAL AND CLINICAL (2022)

Add to Collection

Article Neurosciences

A contrast-adaptive method for simultaneous whole-brain and lesion segmentation in multiple sclerosis

Stefano Cerri et al.

Summary: The method presented in the study allows for the simultaneous segmentation of white matter lesions and normal-appearing neuroanatomical structures in multiple sclerosis patients, showing robust performance in lesion segmentation and segmenting other brain structures. The algorithm is contrast-adaptive and validated across different datasets, and can also be safely applied to MRI scans of healthy controls.

NEUROIMAGE (2021)

Add to Collection

Article Clinical Neurology

Dynamics of pseudo-atrophy in RRMS reveals predominant gray matter compartmentalization

Nicola De Stefano et al.

Summary: The study aimed to assess the dynamics of pseudo-atrophy in MS patients undergoing anti-inflammatory therapies, showing significantly accelerated brain volume loss in the treated group compared to the placebo group. Additionally, similar changes were observed in patients initially on placebo but later switched to IFN beta-1a treatment. The findings highlight the importance of considering significant GM volume changes in clinical trials using MRI-derived GM volume loss as an outcome measure.

ANNALS OF CLINICAL AND TRANSLATIONAL NEUROLOGY (2021)

Add to Collection

Article Clinical Neurology

Brain atrophy rates in patients with multiple sclerosis on long term natalizumab resembles healthy controls

Enrique Alvarez et al.

Summary: The study compared brain atrophy rates in stable multiple sclerosis patients on long-term natalizumab treatment with healthy non-MS controls. The results showed that the two groups had similar brain volume loss and patient reported outcomes, but the MS patients performed slightly worse in cognitive tests.

MULTIPLE SCLEROSIS AND RELATED DISORDERS (2021)

Add to Collection

Article Clinical Neurology

Serum Neurofilament Light Association With Progression in Natalizumab-Treated Patients With Relapsing-Remitting Multiple Sclerosis

Claire Bridel et al.

Summary: This study investigated the potential of serum neurofilament light (NfL) to reflect or predict progression in RRMS patients treated with natalizumab, finding that NfL fails to capture or predict progression largely independently of acute inflammatory disease activity. Additional biomarkers may be needed to monitor progression in these patients.

NEUROLOGY (2021)

Add to Collection

Article Clinical Neurology

Prognostic Accuracy of NEDA-3 in Long-term Outcomes of Multiple Sclerosis

Luca Prosperini et al.

Summary: This study found that about one in four relapsing-remitting multiple sclerosis patients achieved NEDA-3 status in the first 2 years but experienced disability accrual in the following years. Different risk factors were associated with relapse-associated worsening and progression independent from relapse activity, suggesting alternative mechanisms for disability accrual.

NEUROLOGY-NEUROIMMUNOLOGY & NEUROINFLAMMATION (2021)

Add to Collection

Review Medicine, General & Internal